Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: CRISPR gene-editing quality control
Company stage: Pre-clinical
Diseases (gene editing): Sickle-cell disease, genetic blindness, amyloidosis (ATTR), type I diabetes
Genome editing tool: CRISPR/Cas9
Funding stage: Private
Location: San Diego, California, USA
CRISPR QC provides unique insights on CRISPR mechanics (i.e. cleavage activity, gRNA binding, complex stability), allowing therapeutic companies to optimize gene-editing outcomes.